Showing 2011-2020 of 5696 results for "".
- Market Scope: Ophthalmic Deals Surge in 2018-2019; Most Transactions Involve New Ventureshttps://modernod.com/news/market-scope-ophthalmic-deals-surge-in-2018-2019-most-transactions-involve-new-ventures/2477195/Ophthalmic deals garnered over $9 billion from January 2018 through October 2019, driven largely by dry eye and retina related fundraising. Over 100 transactions occurred during this period, and over 80 percent of transaction are categorized as new ventures. The Novartis acquisition of Xii
- Bausch Health Licenses Novaliq’s NOV03 Investigational Treatment For Dry Eye Disease Associated With Meibomian Gland Dysfunctionhttps://modernod.com/news/bausch-health-licenses-novaliqs-nov03-investigational-treatment-for-dry-eye-disease-associated-with-meibomian-gland-dysfunction/2477185/Bausch Health Companies and Novaliq have announced that Bausch Health has acquired an exclusive license for the commercialization and development in the United States and Canada of the investigational treatment NOV03 (perfluorohexy
- NIH Launches First U.S. Clinical Trial of Patient-Derived Stem Cell Therapy to Replace Dying Cells in Retinahttps://modernod.com/news/nih-launches-first-u-s-clinical-trial-of-patient-derived-stem-cell-therapy-to-replace-dying-cells-in-retina/2477175/Researchers at the National Eye Institute (NEI) are launching a clinical trial to test the safety of a novel patient-specific stem cell-based therapy to treat geographic atrophy, the advanced dry form of age-related macular degeneration (AMD). Geographic atrophy currently has no treatment.
- Novartis Receives Positive CHMP Opinion for Beovu (Brolucizumab) for the Treatment of Wet AMDhttps://modernod.com/news/novartis-receives-positive-chmp-opinion-for-beovu-brolucizumab-for-the-treatment-of-wet-amd/2477172/Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Beovu (brolucizumab 6 mg), also known as RTH258, an investigational product for the treatment of wet age-related macular degeneration (AMD).<
- Limelight Bio Emerges with $75 Million to Develop Next Generation Gene Therapieshttps://modernod.com/news/limelight-bio-emerges-with-75-million-to-develop-next-generation-gene-therapies/2477141/Limelight Bio, a privately held, multi-platform, multi-disease biopharmaceutical company developing novel gene therapies, raised $75 million in new financing funded by Apple Tree Partners (ATP), a life sciences innovation fund. Founded in 2017, Limelight Bio has developed proprietary technologies
- Novartis Harnessing AI in Amazon Partnership Aimed at Revamping Drug Manufacturing, Supplyhttps://modernod.com/news/novartis-harnessing-ai-in-amazon-partnership-aimed-at-revamping-drug-manufacturing-supply/2477142/Novartis announced Wednesday that it will work with Amazon’s cloud-computing unit to build a data and analytics platform that seeks to “re-invent” the way medicines are manufactured and delivered. “Four years ago, we started our journey with AWS (Amazon Web Servi
- Tarsius Pharma Announces Granting of Orphan Drug Designation for TRS by the European Medicines Agencyhttps://modernod.com/news/tarsius-pharma-announces-granting-of-orphan-drug-designation-for-trs-by-the-european-medicines-agency/2477104/Tarsius Pharma announced that the European Medicines Agency (EMA) approved the designation of orphan drug for its TRS for treatment of noninfectious uveitis and has acknowledged the clinically relevant advantage for TRS in noninfectious uveitis patients with glaucoma not eligible for corticostero
- EyePoint Pharmaceuticals Appoints George O. Elston as Chief Financial Officer and Head of Corporate Developmenthttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-george-o-elston-as-chief-financial-officer-and-head-of-corporate-development/2477091/EyePoint Pharmaceuticals announced the appointment of George O. Elston as Chief Financial Officer and Head of Corporate Development. Mr. Elston has previously been a consultant to the company and will now transition into this permanent role effective immediately. In this role, Mr. Elston will lea
- Novaliq and Jiangsu Hengrui Medicine Announce a Collaboration for Investigational NOV03 and CyclASol in Chinahttps://modernod.com/news/novaliq-and-jiangsu-hengrui-medicine-announce-a-strategic-collaboration-in-ophthalmology-for-the-eyesol-based-investigational-products-nov03-and-cyclasol-in-china/2477080/Novaliq and Jiangsu Hengrui Medicine, a biopharmaceutical company based in China, announced the closing of an exclusive license agreement to develop, manufacture and commercialize water-free drugs NOV03 and CyclASol for the treatment of dry eye disease in the People’s Republic of China (including
- Aerie Pharmaceuticals Announces the Appointment of David A. Hollander, MD, MBA, as Chief Research & Development Officerhttps://modernod.com/news/aerie-pharmaceuticals-announces-the-appointment-of-david-a-hollander-md-mba-as-chief-research-development-officer/2477056/Aerie Pharmaceuticals announced the appointment of David A. Hollander, MD, MBA, as Chief Research & Development Officer, an executive officer position reporting to Vicente Anido, Jr., PhD, Aerie’s Chairman and Chief Executive Officer. Dr. Hollander will commence his employment at Aerie on Nov